Assembly Bio's ABI-6250 Shows Clean Safety and Target Engagement in Phase 1a
ASMB is trading near its 52-week low of $21.795 (4.5% above the low) on light trading volume (0.1× avg).
Summary
Assembly Bio unveiled positive Phase 1a data for ABI-6250, its oral NTCP inhibitor for hepatitis delta and cholestatic liver diseases. The drug was well tolerated with no serious adverse events and showed dose-dependent bile acid increases confirming target engagement. The pharmacodynamic analysis earned a Poster of Distinction at AASLD. Management plans to start Phase 2 in chronic HDV in Q4 2026 and in PBC/PSC in Q1 2027. This is the first clinical data readout for the program and de-risks the mechanism ahead of pivotal trials. The stock trades near its 52-week low, so positive data could drive a re-rating.
At the time of this announcement, ASMB was trading at $22.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $463.9M. The 52-week trading range was $21.80 to $39.71. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.